Orchestra Biomed Holdings Inc
NASDAQ:OBIO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Orchestra Biomed Holdings Inc
Other Long-Term Assets
Orchestra Biomed Holdings Inc
Other Long-Term Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Long-Term Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
O
|
Orchestra Biomed Holdings Inc
NASDAQ:OBIO
|
Other Long-Term Assets
$1.2m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Other Long-Term Assets
$4.4B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
23%
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Other Long-Term Assets
$1.9B
|
CAGR 3-Years
31%
|
CAGR 5-Years
41%
|
CAGR 10-Years
19%
|
|
|
Stryker Corp
NYSE:SYK
|
Other Long-Term Assets
$3.7B
|
CAGR 3-Years
3%
|
CAGR 5-Years
4%
|
CAGR 10-Years
12%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Other Long-Term Assets
$18.4B
|
CAGR 3-Years
42%
|
CAGR 5-Years
38%
|
CAGR 10-Years
22%
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Other Long-Term Assets
$1.7B
|
CAGR 3-Years
11%
|
CAGR 5-Years
16%
|
CAGR 10-Years
26%
|
|
Orchestra Biomed Holdings Inc
Glance View
Orchestra Biomed Holdings, Inc. engages in the provision of biomedical technologies to patients through risk-reward-sharing partnerships with medical device companies. The company is headquartered in New Hope, Pennsylvania. The company went IPO on 2020-08-04. The company is engaged in developing technologies for patients through risk-reward sharing partnerships with medical device companies. Its flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) and Virtue Sirolimus AngioInfusion Balloon (SAB). BackBeat CNT is a bioelectronic treatment for hypertension that is designed to drive an immediate reduction in blood pressure while simultaneously modulating autonomic nervous system responses to maintain the reduction. Virtue SAB is a patented drug/device combination product candidate in development for the treatment of certain forms of artery disease that is designed to deliver an investigational, extended-release formulation of sirolimus, SirolimusEFR, to the vessel wall during balloon angioplasty without any coating on the balloon surface or the need to leave a stent or other permanent implant in the artery.
See Also
What is Orchestra Biomed Holdings Inc's Other Long-Term Assets?
Other Long-Term Assets
1.2m
USD
Based on the financial report for Dec 31, 2025, Orchestra Biomed Holdings Inc's Other Long-Term Assets amounts to 1.2m USD.
What is Orchestra Biomed Holdings Inc's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 5Y
15%
Over the last year, the Other Long-Term Assets growth was 22%. The average annual Other Long-Term Assets growth rates for Orchestra Biomed Holdings Inc have been -36% over the past three years , 15% over the past five years .
